[
  {
    "date": "2023-12-31",
    "symbol": "MYNZ",
    "period": "FY",
    "cash": 7070925,
    "tradeandothercurrentreceivables": 93555,
    "inventories": 613638,
    "currentprepaidexpenses": 1201670,
    "currentassets": 8979788,
    "propertyplantandequipment": 1702317,
    "intangibleassetsotherthangoodwill": 3394645,
    "rightofuseassets": 1332170,
    "otherassets": 108,
    "assets": 15409028,
    "tradeandothercurrentpayables": 3451615,
    "tradeandothercurrentpayablestorelatedparties": 32702,
    "deferredtaxliabilities": 138889,
    "currentdebtinstrumentsissued": 4903310,
    "otherconvertibledebtcurrent": 33118,
    "intellectualpropertyacquisitionliabilitycurrent": 388839,
    "currentleaseliabilities": 288463,
    "currentliabilities": 9236936,
    "silentpartnershipsnoncurrent": 758812,
    "othersilentpartnershipsnoncurrent": 271354,
    "noncurrentleaseliabilities": 1165723,
    "intellectualpropertyacquisitionliabilitynoncurrent": 726977,
    "liabilities": 12159802,
    "issuedcapital": 235818,
    "sharepremium": 51507526,
    "otherreserves": 21286215,
    "retainedearnings": -69328021,
    "accumulatedothercomprehensiveincome": -452312,
    "equity": 3249226,
    "equityandliabilities": 15409028,
    "revenue": 895479,
    "costofsales": 385820,
    "grossprofit": 509659,
    "salesandmarketingexpense": 6158477,
    "researchanddevelopmentexpense": 9590393,
    "generalandadministrativeexpense": 11405471,
    "operatingexpense": 27154341,
    "profitlossfromoperatingactivities": -26644682,
    "otherincome": 601421,
    "gainslossesonchangeinfairvalueofderivatives": 661000,
    "gainondebtforgivenessrelatedparty": 48677,
    "financecosts": 250000,
    "interestexpense": 559581,
    "interestrevenueexpense": -152562,
    "otheroperatingincomeexpense": 348955,
    "profitlossbeforetax": -26295727,
    "profitloss": -26295727,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -504494,
    "comprehensiveincome": -26800221,
    "basicearningslosspershare": -1.62,
    "weightedaverageshares": 16242334,
    "dilutedearningslosspershare": -1.62,
    "numberofsharesoutstanding": 21165482,
    "issueofequity": 13638,
    "issueofordinarysharesforconversionofdebtinshares": 1259019,
    "increasedecreasethroughsaleofordinarysharesandwarrants": 48538,
    "saleofordinarysharesandwarrants": 4474032,
    "increasedecreasethroughexerciseofwarrantsequity": 3333,
    "increasedecreaseinnumberofordinarysharesissued": 305771,
    "issuanceofordinarysharesforcommitmentfee": 593,
    "issuanceofordinarysharesforcommitmentfeeinshares": 54428,
    "increasedecreasethroughacquisitionofsubsidiary": 3270,
    "issuanceofordinarysharesforacquisitionofintangibleassetinshares": 300000,
    "increasedecreasethroughsharebasedpaymenttransactions": 1550,
    "sharebasedexpense": 142775,
    "increasedecreasethroughexerciseofoptions": 3207789,
    "profitlossfromcontinuingoperations": 26295727,
    "adjustmentsforsharebasedpayments": 4005629,
    "adjustmentsfordepreciationandamortisationexpense": 866412,
    "adjustmentsforprovisions": 14357,
    "adjustmntsforinventorywritedown": 76682,
    "adjustmentsforinterestexpense": 168109,
    "adjustmentsforfairvaluegainslosses": -661000,
    "adjustmentsfordebtforgivenessrelatedparty": -48677,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 15544,
    "adjustmentsfordecreaseincreaseininventories": 500187,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": 239703,
    "adjustmentsforincreasedecreaseindeferredrevenue": -60521,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 720237,
    "cashflowsfromusedinoperatingactivities": -21938845,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 700000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 1198841,
    "cashflowsfromusedininvestingactivities": -1898841,
    "proceedsfromissuingshares": 6392751,
    "proceedsfromissueofbondsnotesanddebentures": 10120000,
    "repaymentsofbondsnotesanddebentures": 1100000,
    "paymentsonsilentpartnerships": 771495,
    "paymentsonsilentpartnershipsrelatedparty": 162255,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 252309,
    "cashflowsfromusedinfinancingactivities": 14226692,
    "effectofexchangeratechangesoncashandcashequivalents": -459856,
    "increasedecreaseincashandcashequivalents": -10070850,
    "cashandcashequivalents": 7070925,
    "interestpaidclassifiedasnoncashinvestingandfinancingactivities": 153580,
    "rightofuseassetadditions": 1009638,
    "acquisitionofintangibleassetforpayableandstockpayable": 3271828,
    "issuanceofordinarysharesforcashlessexercise": 15465,
    "issuanceofcommonstockforconversionofdebtandaccruedinterest": 3000000,
    "concentrationsdisclosuretextblock": "20.CONCENTRATIONS Majorcustomers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. Forthe year ended December 31, 2023, 2022, and 2021, the Company had revenue from one, two, and four, customers that accountedfor approximately 21%, 38% and 56% of revenue, respectively.",
    "convertibledebtpolicytextblock": "Convertible Debt",
    "segmentreportpolicytextblock": "<p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif\"><b>SegmentReport</b></span></p><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif\">TheCompany operates in one operating segment, genetic diagnostic testing.</span></p>",
    "explanationofmeasurementbasesusedinpreparingfinancialstatements": "CriticalAccounting Estimates and Significant Management Judgments",
    "scheduleofestimatedusefullivestabletextblock": "Theestimated useful lives are:",
    "scheduleoftradeandotherreceivablestabletextblock": "December 31,      December 31,             2023      2022       Trade receivables     $121,735      $130,588       Less: allowance for doubtful accounts      (28,180)      (66,852)      Trade receivables, net      93,555       63,736                              Other      -       3,248             $93,555      $66,984",
    "disclosureofinventoriestextblock": "December 31,      December 31,             2023      2022       Raw materials     $430,004      $175,469       Finished goods      240,467       -              670,471       175,469       Less: Reserve      (56,833)      -             $613,638      $175,469",
    "disclosureofprepaidandothercurrentassetsexplanatorytabletextblock": "December 31,      December 31,             2023      2022       Prepaid insurance     $478,116      $624,033       Other prepaid expense      327,538       55,356       Security deposit      135,061       122,570       VAT receivable      260,955       192,154             $1,201,670      $994,113",
    "disclosureofdetailedinformationaboutfutureleasepaymentsweremeasuredusinganincrementalborrowingexplanatory": "TheCompany’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease paymentswere measured using an weighted average incremental borrowing rate of 9.80% per annum as of December 31, 2023.",
    "disclosureofdetailedinformationaboutleaseliabilitiesexplanatory": "December 31,    2023       Lease liabilities             Current portion     $288,463       Long-term portion      1,165,723       Total lease liabilities     $1,454,186",
    "disclosureofdetailedinformationaboutcommittedtominimumleasepaymentsexplanatory": "AtDecember 31, 2023, the Company is committed to minimum lease payments as follows:",
    "scheduleofaccountspayableandaccruedexpensestabletextblock": "December 31,      December 31,             2023      2022       Accounts payable     $2,326,439      $1,333,044       Accrued expenses      992,442       1,037,532       Payroll liabilities      132,734       346,693             $3,451,615      $2,717,269",
    "scheduleofconvertibledebttabletextblock": "Acontinuity of the Company’s Convertible Debt is as follows:",
    "scheduleofconvertibleloantabletextblock": "Acontinuity of the Company’s Convertible loan is as follows:",
    "scheduleofconvertiblenotestabletextblock": "Changesin the balance of the convertible notes are as follows:",
    "scheduleofpromissorynotestabletextblock": "Asummary of the Company’s significant inputs into the fair value of the Promissory Notes is as follows:",
    "scheduleofloanspayabletabletextblock": "Acontinuity of the Company’s loans payable is as follows:",
    "disclosureofcontinuityofthecompanyssilentpartnershipstextblock": "Certainof the Silent Partnership agreements are with a German based bank, which also owns ordinary shares of the Company. Those debts are classifiedas “related party” in the statement of financial position. A continuity of the Company’s silent partnerships is asfollows:",
    "scheduleofremunerationofdirectorsandkeymanagementtabletextblock": "Years    ended December 31,              2023       2022       2021       Salaries and benefits     $1,647,186      $1,291,058      $673,464",
    "disclosureofremunerationpaidtorelatedpartiestextblock": "Remunerationpaid to related parties other than key personnel during the year ended December 31, 2023, 2022, and 2021 was as follows:",
    "disclosureofresearchanddevelopmenttabletextblock": "TheCompany receives government grants related to its research and development activities. The amount of government grants received duringthe years ended December 31, 2023, 2022 and 2021 and recognized as other income were as follows:",
    "disclosureoffederalstatutorytaxratetabletextblock": "Theprovision for income taxes differs from the amount that would have resulted in applying the combined federal statutory tax rate as follows:",
    "scheduleofdeferredtaxassetsandliabilitiestextblock": "Temporarydifferences that give rise to the following deferred tax assets and liabilities at are:",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P5Y",
    "descriptionofusefullifepropertyplantandequipment": "Lease terms",
    "tradereceivables": 121735,
    "allowanceaccountforcreditlossesoffinancialassets": 28180,
    "tradeandotherreceivables": 93555,
    "totaltradeandotherreceivables": 93555,
    "rawmaterials": 430004,
    "finishedgoods": 240467,
    "otherinventories": 670471,
    "lessreserves": 56833,
    "prepayments": 478116,
    "otherprepaidexpense": 327538,
    "longtermdeposits": 135061,
    "valueaddedtaxreceivables": 260955,
    "cost": 1494732,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 932125,
    "disposalreclassescost": 51509,
    "effectsofcurrencytranslation": 34945,
    "accumulateddepreciation": 184149,
    "depreciationexpense": 137996,
    "disposalreclasses": 36039,
    "accumulateddepreciationeffectsofcurrencytranslation": 4359,
    "propertyplantandequipmentgrosscarryingamountfullydepreciated": 1310583,
    "intangibleassetsandgoodwill": 3394645,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 3771828,
    "amortisationintangibleassetsotherthangoodwill": 377183,
    "rightofuseassetsrevaluedassetsatcost": 28429,
    "additions": 38943,
    "reductionleasecost": -36907,
    "effectsofcurrencytranslationrightsofassets": 1110,
    "amountofaccumulateddepreciation": 17927,
    "depreciationrightofuseassets": 4684,
    "reductionaccumulatedamortization": -8000,
    "accumulateddepreciationeffectsofcurrencytranslations": 536,
    "leaseliabilities": 1454186,
    "additionsleaseliabilities": 697103,
    "reductionleaseliabilities": -274790,
    "interestexpenseonleaseliabilities": 147107,
    "leasepayments": -399416,
    "effectsofcurrencytranslationleaseliabilities": 39710,
    "grossleaseliabilities": 367033,
    "amountrepresentingimplicitinterest": -466786,
    "othercurrentpayables": 2326439,
    "accrualsclassifiedascurrent": 992442,
    "currentpayrollliabilities": 132734,
    "effectsofcurrencytranslationconvertibledebt": 937,
    "convertibleloan": 44310,
    "increasedecreasethroughnetexchangedifferencesotherprovisions": 1253,
    "notesanddebenturesissued": 4.9986,
    "convertiblenotescarryingvalue": 4859000,
    "issuanceofconvertiblepromissorynotesfacevalue": 11000000,
    "issuanceofconvertiblepromissorynotescarryingamountatfairvalue": 10120000,
    "repaymentsofconvertiblepromissorynotes": 1100000,
    "repaymentsofconvertiblepromissorynotescarryingvalue": 1100000,
    "conversionofnoteswithordinarysharesfacevalue": 3500000,
    "conversionofnoteswithordinarysharesincarryingamountatfairvalue": 3500000,
    "financialliabilitiesatfairvalue": -661000,
    "descriptionofsensitivityoffairvaluemeasurementtochangesinunobservableinputsliabilities": 4.82,
    "silentpartnerships": 596257,
    "silentpartnershipsaccretion": 42063,
    "effectsofcurrencytranslationamount": 16835,
    "silentpartnershipsextinguishedduringtheyear": -507959,
    "silentpartnershipsgainondebtforgivenessrelatedparty": -48667,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 6597500,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 1.86,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P5Y",
    "numberofinstrumentsotherequityinstrumentsgranted": 4166667,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 1.2,
    "weightedaverageremainingcontractuallifeofoutstandingsharesgranted": "P5Y",
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 816667,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 3,
    "weightedaveragelifeyearsexercised": "P2Y8M15D",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions": "P3Y4M20D",
    "exercisepriceshareoptionsgranted2019": 1.99,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.84,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0348,
    "numberofoutstandingshareoptions": 2727150,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 6.89,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 417500,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 4.48,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 52000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 6.97,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsweightedaveragelifeyearsbalanceending": "P8Y5M8D",
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 1766782,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 6.25,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptionsofvested": "P7Y11M26D",
    "numberofoutstandingstockoptionsoutstandingexpectedtovest": 960368,
    "weightedaveragelifeyearsexpectedtovest": "P2Y7M9D",
    "employeebenefitsexpense": 1647186,
    "salariesandbenefitamount": 29468,
    "multimarkertestfortheearlydetectionofpancreaticcancer": 27741,
    "totalresearchanddevelopmentprojects": 27741,
    "accountspayableandaccruedliabilities": 3451615,
    "convertiblepromissorynote": 4859000,
    "issueofconvertibleinstruments": 250000,
    "tradeandotherpayablestorelatedparties": 238839,
    "profitlossattributabletoownersofparent": -26295727,
    "statutoryincometaxrate": 0.25,
    "taxeffectfromchangeintaxrate": 6574000,
    "permanentdifferences": 904000,
    "taxeffectofforeigntaxrates": -5695000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 25000,
    "netoperatinglosscarryforwards": 2704532,
    "deferredtaxassetsnotrecognized": -2704532,
    "wagesandsalaries": 1442952,
    "stockbasedcompensation": 3266702,
    "professionalfeesexpense": 909046,
    "labandofficeexpenses": 975315,
    "officeexpenses": 21746,
    "insuranceexpense": 817181,
    "travelandentertainment": 84082,
    "sellinggeneralandadministrativeexpense": 11405471,
    "advertisingexpense": 3697523,
    "reserveofgainsandlossesonremeasuringavailableforsalefinancialassets": 69328021,
    "dividendsreceivedclassifiedasoperatingactivities": 21938845,
    "revenuefromsaleofpublications": 16500000,
    "numberofoperatingsegment": 1,
    "commonsharevalue": 3216649,
    "commonsharepershare": 0.54,
    "currenttradereceivables": 38672,
    "expenserecognisedduringperiodforbadanddoubtfuldebts": 53295,
    "numberofsharesissued": 307365,
    "parvaluepershare": 0.01,
    "additionsfromacquisitionsinvestmentproperty": 1115816,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.02,
    "averageexpectedlife": "P5Y54D",
    "presentvalueoffutureleasepaymentspercentage": 0.098,
    "borrowingsinterestrate": 0.15,
    "otherpayables": 30000,
    "convertibleloanspercentage": 0.005,
    "dividendspaidordinarysharespershare": 1,
    "loansreceived": 80278,
    "amountspayableondemandthatarisefromcontractswithinscopeofifrs17": 40139,
    "percentageofcommonsharesoutstanding": 0.0425,
    "percentageofprincipalamount": 0.92,
    "nominalorprincipalamountoffinancialinstrumentondiscontinuationofmeasurementatfairvaluethroughprofitorlossbecausecreditderivativeisusedtomanagecreditrisk": 1100000,
    "promissorynotematurity": "P1Y",
    "promissorynotepremiumpercentage": 0.08,
    "businessdays": "P5D",
    "calendardays": "P30D",
    "percentageofvolumeweightedaverageprice": 1.1,
    "tradingdays": "P8D",
    "derivativefloorpriceofpershare": 2,
    "debtinstrumentconvertiblethresholdconsecutivetradingdays": "P5Y",
    "monthlypayment": 550000,
    "percentageofredemptionpremium": 0.08,
    "percentageofmonthlypayment": 0.1,
    "percentageofalloutstanding": 0.5,
    "feeandcommissionexpense": 250000,
    "numberofsharesauthorised": 54428,
    "facevalue": 5500000,
    "originalissuediscount": 440000,
    "financialassetsatfairvalue": 5060000,
    "debtinstrumentconvertibleconversionprice": 2,
    "balanceamount": 4859000,
    "loanbearsinterest": 0.001,
    "tradereceivablespercentage": 0.001,
    "accruesinterestamount": 0.04,
    "lineofcontrol": 0.005,
    "percentageofentitysrevenue": 0.0166,
    "percentageofoptiontodemandanadditionalpayment": 0.085,
    "initialfairvalueofspasdetermined": 772568,
    "estimatedeffectiveinterestrate": 0.115,
    "agreementsloans": 798694,
    "percentageofspas": 0.085,
    "repaymentofloans": 398634,
    "loansmaturitydate": "December 31, 2025",
    "percentageofloansinterestrate": 0.085,
    "percentageofprincipalofloans": 0.3,
    "percentageofinitialfairvalueofspasdetermined": 0.085,
    "lenderscontributionamount": 676366,
    "shareacquired": 27752,
    "repaymentofspas": 150000,
    "carryingvalue": 200000,
    "spasowingtomajorshareholders": 271354,
    "percentageofspasowingtomajorshareholders": 0.085,
    "loandue": 200000,
    "loansduedate": "2025-12-31",
    "ordinarysharesauthorized": 45000000,
    "commonstocksvotingrights": "one",
    "netproceeds": 1894742,
    "numberofsharesissuedandfullypaid": 142775,
    "amountofsharesissuedforservices": 547840,
    "otherintangibleassets": 2055000,
    "issueofordinarysharesforconversionofdebt": 3500000,
    "stockoptions": 1407766,
    "sharebasedcompensation": 3207789,
    "unamortizedexpense": 3315321,
    "accruedmanagementsalaries": 267234,
    "interestexpenseonborrowings": 26469,
    "incurredaccretionexpense": 10712,
    "recordedexpenses": 57039,
    "paidcost": 885335,
    "insurancerevenueamountsrelatingtochangesinliabilityforremainingcoverage": 1133589,
    "multimarkertest": 6604,
    "baddebtexpense": 14357,
    "unrestrictedcash": 7070925,
    "othercurrentfinancialliabilities": 4859000,
    "foreignexchangeriskdescription": "As the Company operates in Germany it holds a portion of itscash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cashis held in U.S. Dollars, the Company’s reporting currency, which is also the currency of the Company’s largest cash outlaysover the next twenty-four months.",
    "annualrevenuespercentage": 0.1,
    "numberofemployees": 1,
    "noncapitallosses": 36269000,
    "cashpaid": 858415,
    "saleofordinaryshares": 721093,
    "outstandingprincipal": 1246449,
    "interestpayable": 177566,
    "expensesfromallocationofpremiumspaidtoreinsurer": 74995,
    "percentageofpretax": 0.13,
    "carveoutpoolequalpercentage": 0.13,
    "entityregistrantname": "Mainz Biomed N.V.",
    "tradingsymbol": "MYNZ",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 21165482,
    "amendmentflag": "false",
    "entitycentralindexkey": 1874252,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-41010",
    "entityincorporationstatecountrycode": "P7",
    "entityaddressaddressline1": "Mainz Biomed N.V.",
    "entityaddressaddressline2": "Robert Koch Strasse 50",
    "entityaddresspostalzipcode": 55129,
    "entityaddresscityortown": "Mainz",
    "entityaddresscountry": "DE",
    "contactpersonnelname": "Mr. Guido Baechler",
    "cityareacode": 49,
    "localphonenumber": "6131 / 55428-60",
    "contactpersonnelemailaddress": "info@mainzbiomed.com",
    "security12btitle": "Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 6906,
    "auditorname": "Reliant CPA PC",
    "auditorlocation": "Newport Beach, CA"
  },
  {
    "date": "2022-12-31",
    "symbol": "MYNZ",
    "period": "FY",
    "cash": 17141775,
    "tradeandothercurrentreceivables": 259138,
    "inventories": 175469,
    "currentprepaidexpenses": 801959,
    "currentassets": 18378341,
    "propertyplantandequipment": 661692,
    "rightofuseassets": 1177695,
    "otherassets": 23275,
    "assets": 20241003,
    "accountspayableandaccruedliabilities": 2656679,
    "accruedmanagementsalariespayable": 260000,
    "noncurrentdebtinstrumentsissued": 43057,
    "currentdebtinstrumentsissued": 32181,
    "currentconvertibledebt1": 759168,
    "silentpartnershipsrelatedparty": 206167,
    "currentleaseliabilities": 187659,
    "currentliabilities": 4242606,
    "silentpartnership": 687128,
    "silentpartnershiprelatedpartynoncurrents": 256086,
    "noncurrentleaseliabilities": 959116,
    "liabilities": 6144936,
    "issuedcapital": 164896,
    "sharepremium": 38831542,
    "otherreserves": 18079741,
    "retainedearnings": -43032294,
    "accumulatedothercomprehensiveincome": 52182,
    "equity": 52182,
    "equityandliabilities": 20241003,
    "revenue": 529877,
    "costofsales": 347726,
    "grossprofit": 182151,
    "generalandadministrativeexpense": 17328942,
    "salesandmarketingexpense": 5702143,
    "researchanddevelopmentexpense": 3660495,
    "operatingexpense": 26691580,
    "profitlossfromoperatingactivities": -26509429,
    "accretionsexpense": 79628,
    "governmentgrantresearchanddevelopment": 151054,
    "governmentgrantbelowmarketfinancing": 118232,
    "interestexpense": 209696,
    "otherincome": 142131,
    "otheroperatingincomeexpense": 122093,
    "profitlossbeforetax": -26387336,
    "profitloss": -26387336,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 49703,
    "comprehensiveloss": -26337633,
    "basicearningslosspershare": -1.86,
    "weightedaverageshares": 14157492,
    "dilutedearningslosspershare": -1.86,
    "adjustedweightedaverageshares": 14157492,
    "numberofsharesoutstanding": 6000000,
    "issueofequity": 23865889,
    "saleofordinarysharesandwarrants": 1725000,
    "increasedecreasethroughexerciseofwarrantsequity": 382500,
    "increasedecreaseinnumberofordinarysharesissued": 821456,
    "increasedecreasethroughsharebasedpaymenttransactions": 906920,
    "sharebasedexpense": 73000,
    "foreigncurrencytranslation": 49703,
    "increasedecreasethroughexerciseofoptions": 8917236,
    "profitlossfromcontinuingoperations": 26387336,
    "adjustmentsforsharebasedpayments": 9824157,
    "adjustmentsfordepreciationandamortisationexpense": 379798,
    "adjustmentsforprovisions": 65389,
    "adjustmentsforinterestexpense": 79628,
    "governmentgrant": -118232,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -211231,
    "adjustmentsfordecreaseincreaseininventories": -172377,
    "prepaidexpensesandotherassets": 53788,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 1824402,
    "cashflowsfromusedinoperatingactivities": -14769590,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 658483,
    "cashflowsfromusedininvestingactivities": -658483,
    "proceedsfromissuingshares": 23865889,
    "proceedsfromexerciseofwarrants": 906920,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 107027,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 197944,
    "cashflowsfromusedinfinancingactivities": 23943418,
    "effectofexchangeratechangesoncashandcashequivalents": -101112,
    "increasedecreaseincashandcashequivalents": 8414233,
    "cashandcashequivalents": 17141775,
    "rightofuseassetadditions": 1010299,
    "interestpaidclassifiedasnoncashinvestingandfinancingactivities": 125543,
    "disclosureofnatureofoperationsandgoingconcerntextblock": "1.NATURE OF OPERATIONS AND GOING CONCERN ",
    "disclosureofdefinedcontributionagreement": "4.CONTRIBUTION AGREEMENT ",
    "accountspayableandaccruedexpensestextblock": "9.ACCOUNTS PAYABLE AND ACCRUED EXPENSES ",
    "disclosureofconvertibledebtexplanatorytextblock": "10.CONVERTIBLE DEBT – RELATED PARTY ",
    "silentpartnershipstextblock": "12.SILENT PARTNERSHIPS ",
    "relatedpartytransactionstextblock": "14.RELATED PARTY TRANSACTIONS ",
    "concentrationsdisclosuretextblock": "17.CONCENTRATIONS ",
    "convertibledebtpolicytextblock": "ConvertibleDebt ",
    "segmentreportpolicytextblock": "SegmentReport ",
    "scheduleofestimatedusefullivestabletextblock": "      Laboratory    equipment         5 – 10 years      Office    equipment         3 – 10 years      Right-of-use    assets         Lease terms   ",
    "scheduleoftradeandotherreceivablestabletextblock": "            December 31,      December 31,             2022      2021       Accounts receivable     $130,588      $17,995       Less: allowance for doubtful accounts      (66,852)      (796)      Accounts receivable, net      63,736       17,199       VAT receivable      192,154       94,085       Other      3,248       558             $259,138      $111,842   ",
    "disclosureofdetailedinformationaboutfutureleasepaymentsweremeasuredusinganincrementalborrowingexplanatory": "            Total       Balance as of January 1, 2021     $495,051       Additions      32,955       Interest expenses      47,102       Lease payments      (97,429)      Effects of currency    translation      (34,837)      As of December 31, 2021     $442,842       Additions      1,010,299       Interest expenses      94,376       Lease payments      (292,320)      Effects of currency    translation      (10,727)      As of December 31, 2022     $1,244,470    ",
    "disclosureofdetailedinformationaboutleaseliabilitiesexplanatory": "           December 31,      December 31,       Lease liabilities     2022      2021       Current portion     $285,354      $55,076       Long-term portion      959,116       387,766       Total lease liabilities     $1,244,470      $442,842    ",
    "disclosureofdetailedinformationaboutcommittedtominimumleasepaymentsexplanatory": "      Maturity analysis     December 31,    2022       Less than one year     $338,754       One to two years      373,137       Two to three years      279,031       Three to four years      218,632       Four to five years      114,611       More than five years      174,941       Total undiscounted lease liabilities     $1,499,106       Amount representing implicit interest      (254,636)      Lease obligations     $1,244,470   ",
    "scheduleofaccountspayableandaccruedexpensestabletextblock": "            December 31,      December 31,             2022      2021       Accounts payable     $1,333,044      $747,768       Accrued liabilities      1,236,942       26,989       Payroll liabilities      86,693       6,812       Value added taxes payable      -       3,217             $2,656,679      $784,786   ",
    "scheduleofremunerationofdirectorsandkeymanagementtabletextblock": "            Years    ended December 31,             2022      2021      2020       Salaries and    benefits     $1,291,058      $673,464      $202,442    ",
    "disclosureofremunerationpaidtorelatedpartiestextblock": "            Years    ended December 31,             2022      2021      2020       Salaries and    benefits     $-      $943      $15,972    ",
    "scheduleofdeferredtaxassetsandliabilitiestextblock": "            December 31,        2022      December 31,        2021       Deferred tax assets                    Net operating loss carryforwards     $2,717.532      $2,185,532       Deferred tax assets    not recognized      (2,717.532)      (2,185,532)      Net deferred tax asset     $-      $-    ",
    "shareissuerelatedcost": 3216649,
    "cashonhand": 1219855,
    "currentvalueaddedtaxreceivables": 12497,
    "accountspayables": -35443,
    "intangibleassetsotherthangoodwillcarryingamountofrevaluedassets": 1196910,
    "listingexpense": 2019739,
    "identifiableassetsandtransactioncosts": 3216649,
    "accountsreceivable": 130588,
    "allowancefordoubtfulaccounts": 66852,
    "accountsreceivablesnet": 63736,
    "valueaddedtaxreceivables": 192154,
    "tradeandotherreceivables": 3248,
    "totaltradeandotherreceivables": 259138,
    "prepaidinsuranceexpense": 624033,
    "otherprepaidexpense": 55356,
    "longtermdeposits": 122570,
    "currentprepaymentsandothercurrentassets": 801959,
    "cost": 755518,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 658482,
    "effectsofcurrencytranslation": 6648,
    "accumulateddepreciation": 93826,
    "depreciationexpense": 119372,
    "accumulateddepreciationeffectsofcurrencytranslation": -2218,
    "rightofuseassetsrevaluationsurplus": 1556404,
    "additions": 1010300,
    "effectsofcurrencytranslationrightsofassets": -13869,
    "amountofaccumulateddepreciation": 378709,
    "depreciationrightofuseassets": 35866,
    "accumulateddepreciationeffectsofcurrencytranslations": -5588,
    "leaseliabilities": 187659,
    "additionsleaseliabilities": 1010299,
    "interestexpenseonbonds": 94376,
    "leasepayments": -292320,
    "effectsofcurrencytranslationleaseliabilities": -10727,
    "totalleaseliabilities": 1244470,
    "totalundiscountedleaseliabilities": 1499106,
    "amountrepresentingimplicitinterest": -254636,
    "leaseobligations": 1244470,
    "noncurrentpayablestotradesuppliers": 1333044,
    "accrualsclassifiedasnoncurrent": 1236942,
    "noncurrentpayrollliabilities": 86693,
    "noncurrentpayables": 2656679,
    "endingbalanceofloans": 75238,
    "accretionexpenses": 1768,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -4417,
    "extinguished": -108825,
    "effectsofcurrencyamount": -6721,
    "otherprovisions": 1908549,
    "borrowings": 77860,
    "effectsofcurrencytranslationamount": -109430,
    "exercisepriceshareoptionsgranted2019": 20.87,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 6.75,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.79,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0338,
    "warrantoutstandingissuancesindollars": 894500,
    "weightedaverageexercisepriceissuances": 10.73,
    "weightedaveragelifeyearsissuances": 10,
    "warrantoutstandingexercised": -668500,
    "weightedaverageexercisepriceexercised": 3.48,
    "weightedaveragelifeyearsexercised": 2.03,
    "warrantoutstandingforfeited": -5000,
    "weightedaverageexercisepriceforfeited": 15.28,
    "warrantoutstandingsendingbalance": 2394150,
    "weightedaverageexercisepriceendingbalance": 7.18,
    "weightedaveragelifeyearsendingbalance": 9.11,
    "warrantoutstandingexercisable": 1398179,
    "weightedaverageexercisepriceexercisable": 5.24,
    "weightedaveragelifeyearsexercisable": 8.86,
    "employeebenefitsexpense": 1291058,
    "salariesandbenefitamount": 464668,
    "rapiddetectionofantibodybasedpathogens": 42055,
    "multimarkertestfortheearlydetectionofpancreaticcancer": 108999,
    "totalresearchanddevelopmentprojects": 151054,
    "convertibledebtfinancialinstrument": 260000,
    "interestexpenseondebtinstrumentsissued": 75238,
    "silentpartnerships": 943214,
    "profitlossattributabletoownersofparent": -26387336,
    "statutoryincometaxrate": 0.25,
    "taxexpenseincomeatapplicabletaxrate": -6597000,
    "permanentdifferences": 2342000,
    "taxeffectofforeigntaxrates": 3723000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 532000,
    "netoperatinglosscarryforwards": 2717.532,
    "deferredtaxassetsnotrecognized": -2717.532,
    "wagesandsalaries": 3942016,
    "stockbasedcompensation": 8931386,
    "professionalfeesexpense": 2450990,
    "consulting": 741937,
    "officeequipment": 785862,
    "travelandentertainment": 291990,
    "baddebt": 65389,
    "sellinggeneralandadministrativeexpense": 17328942,
    "revenuefromrenderingofinformationtechnologyconsultingservices": 222919,
    "advertisingexpense": 4929598,
    "office": 49092,
    "salesandmarketingtotal": 5702143,
    "salariesandbenefits": 1377542,
    "consultingamount": 660861,
    "officecharges": 1375349,
    "rawmaterials": 140416,
    "depreciationbiologicalassets": 106327,
    "reserveofgainsandlossesonremeasuringavailableforsalefinancialassets": 43032294,
    "dividendsreceivedclassifiedasoperatingactivities": 14769590,
    "netproceeds": 1300000,
    "numberofoperatingsegment": 1,
    "commonsharevalue": 3216649,
    "commonsharepershare": 0.54,
    "loanbearsinterest": 0.001,
    "tradereceivablespercentage": 0.001,
    "accruesinterestamount": 0.04,
    "lineofcontrol": 0.005,
    "percentageofvotingequityinterestsacquired": 0.085,
    "parvaluepershare": 0.01,
    "percentageofentitysrevenue": 0.77,
    "contributionamount": 350000,
    "amountcarryingvalue": 462252,
    "ordinarysharesauthorized": 45000000,
    "commonstocksvotingrights": "one",
    "ordinaryshareissued": 73000,
    "proceedsfromleaseliabilitiesclassifiedasfinancingactivities": 25900000,
    "otherexpensebynature": 23900000,
    "conversionofdebt": 392757,
    "debtconversionconvertedinstrumentamount": 515872,
    "numberofsharesissued": 500000,
    "grantedshares": 894500,
    "stockoptions": 6494112,
    "sharebasedcompensation": 8917237,
    "unamortizeddebtissuanceexpenses": 5115344,
    "ordinarysharesatmarketprices": 0.03,
    "accruedmanagementsalaries": 260000,
    "interestexpenseonborrowings": 32457,
    "incurredaccretionexpense": 14847,
    "recordedexpenses": 97924,
    "paidcost": 97924,
    "antibodybasedpathogens": 81706,
    "unrestrictedcash": 17141775,
    "othercurrentfinancialliabilities": 3889340,
    "foreignexchangeriskdescription": "As the Company operates in Germany it holds a portion of itscash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cashis held in U.S. Dollars, the Company’s reporting currency, which is also the currency of the Company’s largest cash outlaysover the next twenty-four months.",
    "annualrevenuespercentage": 0.1,
    "numberofemployees": 3,
    "noncapitallosses": 21440000,
    "entityregistrantname": "MainzBiomed N.V.",
    "tradingsymbol": "MYNZ",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 14629457,
    "amendmentflag": "false",
    "entitycentralindexkey": 1874252,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non Accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-41010",
    "entityincorporationstatecountrycode": "Netherlands",
    "entityaddresscityortown": "Mainz",
    "entityaddressaddressline1": "MainzBiomed N.V",
    "entityaddressaddressline2": "Robert Koch Strasse 50",
    "entityaddresspostalzipcode": 55129,
    "entityaddresscountry": "Germany",
    "contactpersonnelname": "Mr.Guido Baechler",
    "cityareacode": 49,
    "localphonenumber": "6131 / 55428-60",
    "contactpersonnelemailaddress": "info@mainzbiomed.com",
    "security12btitle": "Ordinary Shares",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 6906,
    "auditorname": "Reliant CPA PC",
    "auditorlocation": "NewportBeach, CA"
  },
  {
    "date": "2021-12-31",
    "symbol": "MYNZ",
    "period": "FY",
    "cash": 8727542,
    "tradeandothercurrentreceivables": 17757,
    "currentprepaidexpenses": 863910,
    "currentassets": 9609209,
    "propertyplantandequipment": 37884,
    "rightofuseassets": 393702,
    "assets": 10040795,
    "accountspayableandaccruedliabilities": 943178,
    "accruedmanagementsalariespayable": 233710,
    "tradeandothercurrentpayablestorelatedparties": 84750,
    "currentdebtinstrumentsissued": 77887,
    "shorttermborrowings": 22754,
    "currentloanspayablerelatedparty": 92792,
    "currentleaseliabilities": 151120,
    "currentliabilities": 1351755,
    "currentconvertibledebt1": 1463981,
    "silentpartnershipsrelatedparty": 476138,
    "noncurrentleaseliabilities": 387766,
    "liabilities": 3679640,
    "issuedcapital": 141075,
    "sharepremium": 13126493,
    "otherreserves": 9736066,
    "retainedearnings": -16644958,
    "accumulatedothercomprehensiveincome": 2479,
    "equity": 2479,
    "equityandliabilities": 10040795,
    "revenue": 577348,
    "costofsales": 399726,
    "grossprofit": 177622,
    "generalandadministrativeexpense": 8478017,
    "salesandmarketingexpense": 957522,
    "researchanddevelopmentexpense": 466689,
    "operatingexpense": 9902228,
    "profitlossfromoperatingactivities": -9724606,
    "accretionsexpense": 139974,
    "governmentgrantresearchanddevelopment": 298997,
    "governmentgrantbelowmarketfinancing": 51410,
    "interestexpense": 199197,
    "otherincome": 43011,
    "acquisitionexpense": 2019739,
    "otheroperatingincomeexpense": -1965492,
    "profitlossbeforetax": -11690098,
    "profitlossfromcontinuingoperations": -11690098,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 204969,
    "comprehensiveloss": -11485129,
    "basicearningslosspershare": -1.62,
    "weightedaverageshares": 7210889,
    "numberofsharesoutstanding": 6000000,
    "issueofordinarysharesforconversionofdebt": 515872,
    "issueofordinarysharesforconversionofdebtinshares": 392757,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossbeforetax": 3216649,
    "recapitalizationtransactioninshares": 3710001,
    "issueofequity": 10425160,
    "issueofordinarysharesinshares": 2300000,
    "increasedecreasethroughsharebasedpaymenttransactions": 6430158,
    "profitloss": -11690098,
    "currencytranslation": 204969,
    "adjustmentsforsharebasedpayments": 6430158,
    "adjustmentsfordepreciationandamortisationexpense": 69929,
    "adjustmentsforinterestexpense": 139974,
    "governmentgrant": 51410,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 24215,
    "prepaidexpensesandotherassets": 833556,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 670725,
    "cashflowsfromusedinoperatingactivities": -3220324,
    "reverseacquisition": 1219856,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 16705,
    "cashflowsfromusedininvestingactivities": 1203151,
    "proceedsfromissuingshares": 10425160,
    "proceedsfromissuingotherequityinstruments": 7673,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 2305,
    "proceedsfromsilentpartnerships": 236636,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 11832,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 49408,
    "cashflowsfromusedinfinancingactivities": 10610534,
    "effectofexchangeratechangesoncashandcashequivalents": 11613,
    "increasedecreaseincashandcashequivalents": 8604974,
    "interestpaidclassifiedasnoncashinvestingandfinancingactivities": 46240,
    "rightofuseassetadditions": 32353,
    "issuanceofcommonstockforshareexchange": 3216649,
    "issuanceofcommonstockforconversionofdebtandaccruedinterest": 508237,
    "disclosureofnatureofoperationsandgoingconcerntextblock": "1.NATURE OF OPERATIONS AND GOING CONCERN ",
    "disclosureofdefinedcontributionagreement": "4.CONTRIBUTION AGREEMENT ",
    "accountspayableandaccruedexpensestextblock": "9.ACCOUNTS PAYABLE AND ACCRUED EXPENSES ",
    "disclosureofconvertibledebtexplanatorytextblock": "10.CONVERTIBLE DEBT – RELATED PARTY ",
    "silentpartnershipstextblock": "12.SILENT PARTNERSHIPS ",
    "relatedpartytransactionstextblock": "15.RELATED PARTY TRANSACTIONS ",
    "concentrationsdisclosuretextblock": "18.CONCENTRATIONS ",
    "convertibledebtpolicytextblock": "Convertible Debt ",
    "segmentreportpolicytextblock": "SegmentReport ",
    "scheduleofestimatedusefullivestabletextblock": "      Laboratory    equipment         5 – 10 years      Office    equipment         3 – 10 years      Right-of-use    assets         Lease terms   ",
    "scheduleoftradeandotherreceivablestabletextblock": "            December 31,      December 31,             2021      2020       Accounts receivable     $17,995      $47,149       Less: allowance for    doubtful accounts      (796)      (3,066)      Accounts receivable, net      17,199       44,083       Other      558       158             $17,757      $44,241                          ",
    "disclosureofdetailedinformationaboutfutureleasepaymentsweremeasuredusinganincrementalborrowingexplanatory": "            Total       Balance as at January 1, 2020     $451,742       Additions      39,850       Interest expenses      47,173       Lease payments      (86,051)      Effects    of currency translation      42,337       As at December 31, 2020     $495,051       Additions      32,955       Interest expenses      47,102       Lease payments      (97,429)      Effects    of currency translation      (34,837)      As at December 31, 2021     $442,842    ",
    "disclosureofdetailedinformationaboutleaseliabilitiesexplanatory": "      Lease liabilities     December 31,    2021      December 31,        2020       Current portion     $55,076      $47,611       Long-term portion      387,766       447,440       Total lease liabilities     $442,842      $495,051    ",
    "disclosureofdetailedinformationaboutcommittedtominimumleasepaymentsexplanatory": "      Maturity analysis     December 31,        2021       Less than one year     $95,663       One to two years      95,663       Two to three years      93,022       Three to four years      86,849       Four to five years      84,892       More than five years      144,204       Total undiscounted lease liabilities     $600,293       Amount representing    implicit interest      (157,451)      Lease obligations     $442,842   ",
    "scheduleofaccountspayableandaccruedexpensestabletextblock": "            December 31,      December 31,             2021      2020       Accounts payable     $747,768      $248,576       Accrued liabilities      26,989       77,016       Payroll liabilities      6,812       53,728       Value added taxes payable      3,217       19,817             $784,786      $399,137   ",
    "scheduleofremunerationofdirectorsandkeymanagementtabletextblock": "            December 31,      December 31,      December 31,             2021      2020      2019       Salaries and    benefits     $673,464      $202,442      $192,423    ",
    "scheduleofremunerationpaidtorelatedpartiestabletextblock": "            December 31,      December 31,      December 31,             2021      2020      2019       Salaries and    benefits     $926      $33,078      $3,500    ",
    "scheduleofdeferredtaxassetsandliabilitiestextblock": "            December    31,     2021      December    31,    2020       Deferred tax assets                      Net operating loss carryforwards     $2,185,532      $1,347,532       Deferred tax assets    not recognized      (2,185,532)      (1,347,532)      Net deferred tax asset     $-      $-    ",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": 10,
    "estimatedusefullivesoftheassets": "Lease terms",
    "shareissuerelatedcost": 3216649,
    "cashonhand": 1219855,
    "valueaddedtaxreceivables": 12497,
    "accountspayables": -35443,
    "intangibleassetsotherthangoodwill": 1196910,
    "listingexpense": 2019739,
    "identifiableassetsandtransactioncosts": 3216649,
    "accountsreceivable": 17995,
    "allowancefordoubtfulaccounts": 796,
    "accountsreceivablesnet": 17199,
    "tradeandotherreceivables": 558,
    "totaltradeandotherreceivables": 17757,
    "insuranceexpense": 743750,
    "otherprepaidexpense": 12590,
    "valueaddedtaxpayables": 94085,
    "depositsfrombanks": 13485,
    "currentprepaymentsandothercurrentassets": 863910,
    "cost": 90388,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 16706,
    "disposalspropertyplantandequipment": 209,
    "effectsofcurrencytranslation": -6446,
    "accumulateddepreciation": 52504,
    "depreciationexpense": 29515,
    "accumulateddepreciationeffectsofcurrencytranslation": -3863,
    "rightofuseassetsrevaluationsurplus": 559973,
    "additions": 32354,
    "effectsofcurrencytranslationrightsofassets": -42484,
    "amountofaccumulateddepreciation": 166271,
    "depreciationrightofuseassets": 8868,
    "accumulateddepreciationeffectsofcurrencytranslations": -10653,
    "leaseliabilities": 151120,
    "additionsleaseliabilities": 32955,
    "interestexpenseonbonds": 47102,
    "leasepayments": -97429,
    "effectsofcurrencytranslationleaseliabilities": -34837,
    "totalundiscountedleaseliabilities": 600293,
    "amountrepresentingimplicitinterest": -157451,
    "leaseobligations": 442842,
    "noncurrentpayablestotradesuppliers": 747768,
    "accrualsclassifiedasnoncurrent": 26989,
    "noncurrentpayrollliabilities": 6812,
    "noncurrentvalueaddedtaxpayables": 3217,
    "noncurrentpayables": 784786,
    "accretionexpenses": 60136,
    "increasedecreasethroughconversionofconvertibleinstruments": -508237,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -7382,
    "endingbalanceofloans": 77887,
    "issuedduringtheyearinshares": 2305,
    "extinguished": -11832,
    "accretions": 1542,
    "effectsofcurrencyamount": -9302,
    "endingbalance": 115546,
    "otherprovisions": 1940119,
    "amountsincurreddeferredacquisitioncostsarisingfrominsurancecontracts": 236636,
    "discount": -51410,
    "borrowings": 78295,
    "effectsofcurrencytranslationamount": -141652,
    "stockpriceattimeofissuanceindollars": 1.602,
    "exercisepriceshareoptionsgranted2019": 10.56,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 10,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.79,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0151,
    "warrantoutstandingexercisable": 895144,
    "weightedaverageexercisepriceexercisable": 5.1,
    "weightedaveragelifeyearsexercisable": 9.86,
    "warrantoutstandingissuancesindollars": 3855000,
    "weightedaverageexercisepriceissuances": 3.08,
    "weightedaveragelifeyearsissuances": 2.13,
    "warrantoutstandingsendingbalance": 1504650,
    "weightedaverageexercisepriceendingbalance": 5.1,
    "weightedaveragelifeyearsendingbalance": 9.85,
    "warrantoutstandinggrants": 1504650,
    "weightedaverageexercisepricegrants": 5.1,
    "weightedaveragelifeyearsgrants": 10,
    "noncurrentinventories": 134057,
    "sellingexpense": 8967,
    "repairsandmaintenanceexpense": 95352,
    "benefitspaidorpayable": 67562,
    "royaltyexpense": 88739,
    "decreasethroughclassifiedasheldforsalepropertyplantandequipment": 5049,
    "employeebenefitsexpense": 673464,
    "salariesandbenefitamount": 926,
    "rapiddetectionofantibodybasedpathogens": 102780,
    "multimarkertestfortheearlydetectionofpancreaticcancer": 196217,
    "totalresearchanddevelopmentprojects": 298997,
    "convertibledebtfinancialinstrument": 81623,
    "loanspayablecontractualmaturities": 121087,
    "silentpartnerships": 2033162,
    "statutoryincometaxrate": 0.25,
    "taxexpenseincomeatapplicabletaxrate": -2923000,
    "permanentdifferences": 1601000,
    "taxeffectofforeigntaxrates": 484000,
    "deferredtaxexpenseincomerelatingtooriginationandreversaloftemporarydifferences": 838000,
    "netoperatinglosscarryforwards": 2185532,
    "deferredtaxassetsnotrecognized": -2185532,
    "officeequipment": 193513,
    "professionalfeesexpense": 805898,
    "wagesandsalaries": 986490,
    "stockbasedcompensation": 6430158,
    "travelandentertainment": 37503,
    "sellinggeneralandadministrativeexpense": 8478017,
    "advertisingexpense": 587018,
    "revenuefromrenderingofinformationtechnologyconsultingservices": 243012,
    "office": 34206,
    "salariesandbenefits": 84418,
    "depreciationbiologicalassets": 26290,
    "consultingamount": 83646,
    "officecharges": 106487,
    "salariesandbenefitsamount": 250266,
    "reserveofgainsandlossesonremeasuringavailableforsalefinancialassets": 16644958,
    "numberofoperatingsegment": 1,
    "commonsharevalue": 3216649,
    "commonsharepershare": 0.54,
    "borrowingsinterestrate": 0.035,
    "convertibleloanspercentage": 0.005,
    "loanamount": 417272,
    "issuedcapitalordinaryshares": 392757,
    "paymentsforshareissuecosts": 485,
    "cashreceived": -7673,
    "percentageofentitysrevenue": 0.56,
    "ordinarysharesauthorized": 45000000,
    "parvaluepershare": 0.01,
    "commonshareissued": 6000000,
    "numberofsharesauthorised": 3510000,
    "grossproceeds": 2200000,
    "warrantissued": 3745000,
    "underwritingwarrant": 140000,
    "underwritingwarrantinamount": 754286,
    "numberofsharesissued": 2300000,
    "grantedshares": 1504650,
    "stockoptions": 13968627,
    "sharebasedcompensation": 6430158,
    "unamortizeddebtissuanceexpenses": 7538469,
    "accruedmanagementsalaries": 233710,
    "interestexpenseonborrowings": 36442,
    "incurredaccretionexpense": 17489,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1683,
    "loansreceivedpercentage": 0.06,
    "consumerloans": 41728,
    "relatedpartybalancesdescription": "Asof December 31, 2021, EUR0 (2020 – EUR30,139 or approximately $36,951) and EUR40,139 (approximately $47,856) (2020 – EUR40,139,or approximately $49,226) of the 2017 Convertible Loans were owing to the Chief Scientific Officer (the “CSO”) and a majorshareholder of the Company, respectively. The amounts are due on demand (Note 9). ",
    "antibodybasedpathogens": 254796,
    "revenuefromgovernmentgrants": 51410,
    "marketinterestrates": 0.03,
    "unrestrictedcash": 8727542,
    "othercurrentfinancialliabilities": 1351755,
    "foreignexchangeriskdescription": "As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between threeto twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reportingcurrency, which is also the currency of the Company’s largest cash outlays over the next twenty-four months.",
    "annualrevenuespercentage": 0.1,
    "numberofemployees": 4,
    "noncapitallosses": 7357000,
    "overallsensitivities": 0.75,
    "crclesions": 0.9500000000000001,
    "specificityoutcome": 0.96,
    "exerciseofwarrantsshares": 202943,
    "netproceeds": 382500,
    "entityregistrantname": "MainzBiomed N.V.",
    "tradingsymbol": "MYNZ",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1874252,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non Accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-41010",
    "entityincorporationstatecountrycode": "Netherlands",
    "entityaddressaddressline1": "MainzBiomed N.V.",
    "entityaddressaddressline2": "Robert Koch Strasse 50",
    "entityaddresspostalzipcode": 55129,
    "entityaddresscityortown": "Mainz",
    "entityaddresscountry": "Germany",
    "contactpersonnelname": "Mr.Guido Baechler",
    "cityareacode": 49,
    "localphonenumber": "6131 / 55428-60",
    "contactpersonnelemailaddress": "info@mainzbiomed.com",
    "security12btitle": "Ordinary Shares",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 5041,
    "auditorname": "BF Borgers CPA PC",
    "auditorlocation": "Lakewood, CO"
  }
]